{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T11:11:48Z","timestamp":1755601908158},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T00:00:00Z","timestamp":1585526400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T00:00:00Z","timestamp":1585526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p><jats:italic>Cryptosporidium<\/jats:italic> sp. are common intracellular parasites responsible of severe diarrhea in T-cell-immunocompromised patients. We report the first case of a woman who contracted cryptosporidiosis after treatment with fingolimod, a drug labeled for multiple sclerosis and responsible for marked lymphopenia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 60-year-old woman was admitted for abdominal pain diarrhea and fever. The patient suffered from multiple sclerosis and had been treated with fingolimod from august 2017 to september 2018 time of occurrence of the first digestive symptoms. Stool culture was negative but parasitological examination was positive for <jats:italic>Cryptosporidium<\/jats:italic> sp. Blood biological examination profound lymphopenia of 240\/mm<jats:sup>3<\/jats:sup> [17 CD4\/mm<jats:sup>3<\/jats:sup> (7%) and 32 CD8\/mm<jats:sup>3<\/jats:sup> (14%)]. Fingolimod was stopped, and the patient was put on nitazoxanide 500\u2009mg bid for 7\u2009days. The diarrhea resolved and no relapse was observed. Six other cases were found in the Pharmacovigilance database.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Physicians should be aware of this association and screen for <jats:italic>Cryptosporidium<\/jats:italic> in cases of diarrhea in patients treated with fingolimod. Patients should be aware of this risk and advise to take appropriate measures to avoid such contamination.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-020-04988-7","type":"journal-article","created":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T18:02:54Z","timestamp":1585591374000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cryptosporidiosis after treatment with fingolimod: a case report and pharmacovigilance review"],"prefix":"10.1186","volume":"20","author":[{"given":"M.","family":"Martinot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Abou-Bacar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Lamothe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Alt","family":"Tebacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Mohseni","family":"Zadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Dalle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Favennec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Brunet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Sellal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,30]]},"reference":[{"issue":"15","key":"4988_CR1","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1080\/14656566.2017.1373093","volume":"18","author":"K Thomas","year":"2017","unstructured":"Thomas K, Proschmann U, Ziemssen T. Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis. Expert Opin Pharmacother. 2017;18(15):1649\u201360.","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"4988_CR2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s40263-018-0488-6","volume":"32","author":"S Faissner","year":"2018","unstructured":"Faissner S, Gold R. Efficacy and safety of the newer multiple sclerosis drugs approved since 2010. CNS Drugs. 2018;32(3):269\u201387.","journal-title":"CNS Drugs"},{"issue":"3","key":"4988_CR3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/cen3.12397","volume":"8","author":"F Yoshii","year":"2017","unstructured":"Yoshii F, et al. Neurological safety of fingolimod: an updated review. Clin Exp Neuroimmunol. 2017;8(3):233\u201343.","journal-title":"Clin Exp Neuroimmunol"},{"issue":"8","key":"4988_CR4","doi-asserted-by":"publisher","first-page":"ofy174","DOI":"10.1093\/ofid\/ofy174","volume":"5","author":"DJ Epstein","year":"2018","unstructured":"Epstein DJ, Dunn J, Deresinski S. Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management. Open Forum Infect Dis. 2018;5(8):ofy174.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"4988_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S1473-3099(14)70772-8","volume":"15","author":"W Checkley","year":"2015","unstructured":"Checkley W, et al. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium. Lancet Infect Dis. 2015;15(1):85\u201394.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"4988_CR6","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.cmi.2016.04.021","volume":"22","author":"SM Caccio","year":"2016","unstructured":"Caccio SM, Chalmers RM. Human cryptosporidiosis in Europe. Clin Microbiol Infect. 2016;22(6):471\u201380.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"4988_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1128\/CMR.00076-12","volume":"26","author":"M Bouzid","year":"2013","unstructured":"Bouzid M, et al. Cryptosporidium pathogenicity and virulence. Clin Microbiol Rev. 2013;26(1):115\u201334.","journal-title":"Clin Microbiol Rev"},{"key":"4988_CR8","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.exppara.2018.08.001","volume":"192","author":"D Costa","year":"2018","unstructured":"Costa D, et al. Human cryptosporidiosis in immunodeficient patients in France (2015-2017). Exp Parasitol. 2018;192:108\u201312.","journal-title":"Exp Parasitol"},{"issue":"9","key":"4988_CR9","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/S1473-3099(17)30276-1","volume":"17","author":"Collaborators, G.B.D.D.D","year":"2017","unstructured":"Collaborators, G.B.D.D.D. Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the global burden of disease study 2015. Lancet Infect Dis. 2017;17(9):909\u201348.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"4988_CR10","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1128\/JCM.43.6.2805-2809.2005","volume":"43","author":"IM Sulaiman","year":"2005","unstructured":"Sulaiman IM, et al. Unique endemicity of cryptosporidiosis in children in Kuwait. J Clin Microbiol. 2005;43(6):2805\u20139.","journal-title":"J Clin Microbiol"},{"issue":"4","key":"4988_CR11","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1586\/eri.09.24","volume":"7","author":"B Pantenburg","year":"2009","unstructured":"Pantenburg B, Cabada MM, White AC Jr. Treatment of cryptosporidiosis. Expert Rev Anti-Infect Ther. 2009;7(4):385\u201391.","journal-title":"Expert Rev Anti-Infect Ther"},{"issue":"4","key":"4988_CR12","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s13311-017-0565-4","volume":"14","author":"BZ Chaudhry","year":"2017","unstructured":"Chaudhry BZ, Cohen JA, Conway DS. Sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis. Neurotherapeutics. 2017;14(4):859\u201373.","journal-title":"Neurotherapeutics"},{"issue":"2","key":"4988_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0228380","volume":"15","author":"M Hjorth","year":"2020","unstructured":"Hjorth M, Dandu N, Mellergard J. Treatment effects of fingolimod in multiple sclerosis: selective changes in peripheral blood lymphocyte subsets. PLoS One. 2020;15(2):e0228380.","journal-title":"PLoS One"},{"issue":"3","key":"4988_CR14","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2217\/fmb.09.128","volume":"5","author":"A Borad","year":"2010","unstructured":"Borad A, Ward H. Human immune responses in cryptosporidiosis. Future Microbiol. 2010;5(3):507\u201319.","journal-title":"Future Microbiol"},{"key":"4988_CR15","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.actatropica.2018.08.018","volume":"187","author":"RJ Wang","year":"2018","unstructured":"Wang RJ, et al. Widespread occurrence of Cryptosporidium infections in patients with HIV\/AIDS: epidemiology, clinical feature, diagnosis, and therapy. Acta Trop. 2018;187:257\u201363.","journal-title":"Acta Trop"},{"issue":"1","key":"4988_CR16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4103\/tp.TP_34_17","volume":"8","author":"S Khurana","year":"2018","unstructured":"Khurana S, Chaudhary P. Laboratory diagnosis of cryptosporidiosis. Trop Parasitol. 2018;8(1):2\u20137.","journal-title":"Trop Parasitol"},{"key":"4988_CR17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1051\/parasite\/2018049","volume":"25","author":"B Autier","year":"2018","unstructured":"Autier B, et al. Comparison of three commercial multiplex PCR assays for the diagnosis of intestinal protozoa. Parasite. 2018;25:48.","journal-title":"Parasite"},{"key":"4988_CR18","doi-asserted-by":"crossref","unstructured":"Morio F, et al. Assessment of the first commercial multiplex PCR kit (ParaGENIE Crypto-Micro Real-Time PCR) for the detection of Cryptosporidium spp., Enterocytozoon bieneusi, and Encephalitozoon intestinalis from fecal samples. Diagn Microbiol Infect Dis. 2019;95(1):34\u20137.","DOI":"10.1016\/j.diagmicrobio.2019.04.004"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-04988-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-020-04988-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-04988-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T23:10:55Z","timestamp":1617059455000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-04988-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,30]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4988"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-04988-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,30]]},"assertion":[{"value":"18 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed written consent for the publication of the case report was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"257"}}